DE60312333D1 - Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung - Google Patents

Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung

Info

Publication number
DE60312333D1
DE60312333D1 DE60312333T DE60312333T DE60312333D1 DE 60312333 D1 DE60312333 D1 DE 60312333D1 DE 60312333 T DE60312333 T DE 60312333T DE 60312333 T DE60312333 T DE 60312333T DE 60312333 D1 DE60312333 D1 DE 60312333D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
solid pharmaceutical
production
composition containing
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60312333T
Other languages
English (en)
Other versions
DE60312333T2 (de
Inventor
Chacra-Vernet Marie-Line Abou
Noel Zakarian
Dominique Toselli
Rene Gimet
Claude Laruelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLL Pharma SA
Original Assignee
CLL Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLL Pharma SA filed Critical CLL Pharma SA
Publication of DE60312333D1 publication Critical patent/DE60312333D1/de
Application granted granted Critical
Publication of DE60312333T2 publication Critical patent/DE60312333T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60312333T 2002-06-25 2003-06-24 Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung Expired - Fee Related DE60312333T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207831 2002-06-25
FR0207831A FR2841138B1 (fr) 2002-06-25 2002-06-25 Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
PCT/FR2003/001933 WO2004000279A1 (fr) 2002-06-25 2003-06-24 Composition pharmaceutique solide contenant un principe actif lipophile, son procédé de préparation

Publications (2)

Publication Number Publication Date
DE60312333D1 true DE60312333D1 (de) 2007-04-19
DE60312333T2 DE60312333T2 (de) 2007-12-20

Family

ID=29720010

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60312333T Expired - Fee Related DE60312333T2 (de) 2002-06-25 2003-06-24 Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung

Country Status (12)

Country Link
US (1) US20080095838A1 (de)
EP (1) EP1521574B1 (de)
JP (1) JP2005533802A (de)
KR (1) KR20050040869A (de)
AT (1) ATE355829T1 (de)
AU (1) AU2003260621A1 (de)
CA (1) CA2490341A1 (de)
DE (1) DE60312333T2 (de)
ES (1) ES2283821T3 (de)
FR (1) FR2841138B1 (de)
WO (1) WO2004000279A1 (de)
ZA (1) ZA200500716B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
ES2483126T3 (es) * 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EA014420B1 (ru) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
JP5219508B2 (ja) 2005-05-18 2013-06-26 大日本住友製薬株式会社 ドロキシドパを含有する安定な錠剤
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
CA2656277A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
EP2119442A4 (de) 2006-12-28 2010-12-15 Astellas Pharma Inc Pharmazeutische zusammensetzung von tacrolimus mit verzögerter freisetzung
WO2009140341A2 (en) * 2008-05-13 2009-11-19 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
US9119820B2 (en) 2008-06-13 2015-09-01 Sumitomo Dainippon Pharma Co., Ltd. Tablet quickly disintegrating in the oral cavity and method for producing the same
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
JP5953646B2 (ja) * 2009-11-24 2016-07-20 大正製薬株式会社 イブプロフェン含有固形製剤
JP5508311B2 (ja) * 2011-02-28 2014-05-28 テバ ファーマシューティカル インダストリーズ リミティド 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
DK2902029T3 (en) 2012-09-25 2018-10-29 Chugai Pharmaceutical Co Ltd RET INHIBITOR
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR102478887B1 (ko) 2014-04-25 2022-12-16 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 고용량 함유하는 제제
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016114375A1 (ja) 2015-01-16 2016-07-21 中外製薬株式会社 併用医薬
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3668484B1 (de) * 2017-08-17 2022-07-13 F. Hoffmann-La Roche AG Neue pharmazeutische zusammensetzungen für basische oder neutrale niedermolekulare verbindungen
WO2019063478A1 (en) * 2017-09-26 2019-04-04 Capsugel Belgium Nv SUB-MICRONIC PARTICLE FORMULATIONS
EP3848361A4 (de) 2018-09-04 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung einer tetracyclischen verbindung
CN114569605A (zh) * 2022-03-10 2022-06-03 沈阳药科大学 阿托伐他汀-黄酮类化合物共无定型复合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
AU1511399A (en) * 1997-12-31 1999-07-19 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
WO2000043041A1 (fr) * 1999-01-22 2000-07-27 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicamenteuses presentant une meilleure absorption orale
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
CA2415643C (en) * 2000-07-17 2010-11-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption

Also Published As

Publication number Publication date
EP1521574A1 (de) 2005-04-13
CA2490341A1 (fr) 2003-12-31
AU2003260621A1 (en) 2004-01-06
FR2841138B1 (fr) 2005-02-25
EP1521574B1 (de) 2007-03-07
KR20050040869A (ko) 2005-05-03
ZA200500716B (en) 2006-09-27
ES2283821T3 (es) 2007-11-01
DE60312333T2 (de) 2007-12-20
FR2841138A1 (fr) 2003-12-26
JP2005533802A (ja) 2005-11-10
WO2004000279A1 (fr) 2003-12-31
ATE355829T1 (de) 2007-03-15
US20080095838A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
WO2003090726A3 (en) Chewable soft capsule
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
WO2004032862A3 (en) Cyclodextrin-based materials, compositions and uses related thereto
EP1428821A8 (de) Piperidin-4-ylamine mit analgetischer Wirksamkeit
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
HUP0004924A2 (hu) Ciklodextrineket tartalmazó gyógyászati készítmények
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
DE60001546D1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
EE9900589A (et) Farmatseutilised kompositsioonid limaskestale kandmiseks
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
ATE326264T1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
IS5851A (is) Ný lyf til inntöku 5-HT4 gerandefna eða mótlyfja
ATE230979T1 (de) Verfahren zur herstellung neuer fenofibrathaltiger arzneiformulierungen, dadurch hergestellte arzneiformulierungen und ihre verwendung
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
MA27662A1 (fr) Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
WO2005041876A3 (en) Spill resistant formulations containing clays

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee